EUVIMEDEUVIMED entdecken
Multizentrische StudieEvaluationsstudieOpen Access · CC BY 4.0

A Prospective Evaluation of the Diagnostic Accuracy of the Point-of-Care VISITECT CD4 Advanced Disease Test in 7 Countries

Tinne Gils iD, Jerry Hella, Bart K M Jacobs, Bianca Sossen, Madalo Mukoka, Monde Muyoyeta, Elizabeth Nakabugo, Hung Van Nguyen, Sasiwimol Ubolyam, Aurélien Macé, Marcia Vermeulen, Sarah Nyangu und 16 weitere

The Journal of Infectious Diseases · 2025

DOI: 10.1093/infdis/jiae374 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von Tinne Gils und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium. Hauptthemen laut MEDLINE: HIV Infections, Point-of-Care Systems, Point-of-Care Testing, Tuberculosis. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Netherlands Enterprise Agency, KfW, National Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

CD4 measurement is pivotal in the management of advanced human immunodeficiency virus (HIV) disease. VISITECT CD4 Advanced Disease (VISITECT; AccuBio, Ltd) is an instrument-free, point-of-care, semiquantitative test allowing visual identification of CD4 ≤ 200 cells/µL or >200 cells/ µL from finger-prick or venous blood.

Methods

As part of a diagnostic accuracy study of FUJIFILM SILVAMP TB LAM, people with HIV ≥18 years old were prospectively recruited in 7 countries from outpatient departments if a tuberculosis symptom was present, and from inpatient departments. Participants provided venous blood for CD4 measurement using flow cytometry (reference standard) and finger-prick blood for VISITECT (index text), performed at point-of-care. Sensitivity, specificity, and positive and negative predictive values of VISITECT to determine CD4 ≤ 200 cells/ µL were evaluated.

Results

Among 1604 participants, the median flow cytometry CD4 was 367 cells/µL (interquartile range, 128–626 cells/µL) and 521 (32.5%) had CD4 ≤ 200 cells/µL. VISITECT sensitivity was 92.7% (483/521; 95% confidence interval [CI], 90.1%–94.7%) and specificity was 61.4% (665/1083; 95% CI, 58.4%–64.3%). For participants with CD4 0–100, 101–200, 201–300, 301–500, and >500 cells/µL, VISITECT misclassified 4.5% (95% CI, 2.5%–7.2%), 12.5 (95% CI, 8.0%–18.2%), 74.1% (95% CI, 67.0%–80.5%), 48.0% (95% CI, 42.5%–53.6%), and 22.6% (95% CI, 19.3%–26.3%), respectively.

Conclusions

VISITECT's sensitivity, but not specificity, met the World Health Organization's minimal sensitivity and specificity threshold of 80% for point-of-care CD4 tests. VISITECT's quality needs to be assessed and its accuracy optimized. VISITECT’s utility as CD4 triage test should be investigated. Clinical Trials Registration. NCT04089423.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsPoint-of-Care SystemsPoint-of-Care TestingTuberculosisAdultFemaleHumansMaleMiddle AgedCD4 Lymphocyte CountFlow CytometryPredictive Value of TestsProspective StudiesSensitivity and Specificity

Stichwörter der Autor:innen

AIDS-related opportunistic infectionsCD4 AntigensHIVpoint-of-caresensitivity and specificity

Autor:innen und Institutionen

  • Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
  • Global Health Institute, University of Antwerp, Wilrijk, Belgium.
  • Ifakara Health Institute, Dar es Salaam, Tanzania.
  • Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
  • Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
  • Public Health Group, Malawi-Liverpool-Wellcome Programme, Blantyre, Malawi.

ORCID-Profile: Tinne Gils, Claudia M Denkinger, Klaus Reither, Morten Ruhwald

Förderung

  • Netherlands Enterprise Agency
  • KfW
  • National Research Foundation
  • Wellcome Trust
  • NIAID NIH HHS
  • Department of Science and Technology
  • Global Health Innovative Technology Fund
  • FIC NIH HHS

Zitieren

APA

Gils, T., Hella, J., Jacobs, B. K. M., Sossen, B., Mukoka, M., Muyoyeta, M., Nakabugo, E., Van Nguyen, H., Ubolyam, S., Macé, A., Vermeulen, M., Nyangu, S., Sanjase, N., Sasamalo, M., Dinh, H. T., Ngo, T. A., Manosuthi, W., Jirajariyavej, S., Denkinger, C. M., …, & Ruhwald, M. (2025). A Prospective Evaluation of the Diagnostic Accuracy of the Point-of-Care VISITECT CD4 Advanced Disease Test in 7 Countries. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae374

Vancouver

Gils T, Hella J, Jacobs BKM, Sossen B, Mukoka M, Muyoyeta M, et al. A Prospective Evaluation of the Diagnostic Accuracy of the Point-of-Care VISITECT CD4 Advanced Disease Test in 7 Countries. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiae374

BibTeX
@article{Gils2025,
  author = {Gils, Tinne and Hella, Jerry and Jacobs, Bart K M and Sossen, Bianca and Mukoka, Madalo and Muyoyeta, Monde and Nakabugo, Elizabeth and Van Nguyen, Hung and Ubolyam, Sasiwimol and Macé, Aurélien and Vermeulen, Marcia and Nyangu, Sarah and Sanjase, Nsala and Sasamalo, Mohamed and Dinh, Huong Thi and Ngo, The Anh and Manosuthi, Weerawat and Jirajariyavej, Supunnee and Denkinger, Claudia M and Nguyen, Nhung Viet and Avihingsanon, Anchalee and Nakiyingi, Lydia and Székely, Rita and Kerkhoff, Andrew D and MacPherson, Peter and Meintjes, Graeme and Reither, Klaus and Ruhwald, Morten},
  title = {A Prospective Evaluation of the Diagnostic Accuracy of the Point-of-Care VISITECT CD4 Advanced Disease Test in 7 Countries},
  journal = {The Journal of Infectious Diseases},
  year = {2025},
  doi = {10.1093/infdis/jiae374}
}
Kostenlos starten →